Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC

A Gerger; W Eisterer; S Fuxius; S Bastian; D Koeberle; M Welslau; DA Sanoyan; C Maas; J Uhlig; K Fenchel; Richard Greil; E von der Heyde; GR Agocs; R Weide; M Schwager; F Reichenbach; DP Modest; R Fritsch

doi:10.21873/anticanres.15982

Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC

A Gerger, W Eisterer, S Fuxius, S Bastian, D Koeberle, M Welslau, DA Sanoyan, C Maas, J Uhlig, K Fenchel, Richard Greil (Co-author), E von der Heyde, GR Agocs, R Weide, M Schwager, F Reichenbach, DP Modest, R Fritsch

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

3 Citations (Web of Science)

Original language	English
Pages (from-to)	4773-4785
Journal	ANTICANCER RESEARCH
Volume	42
Issue number	10
DOIs	https://doi.org/10.21873/anticanres.15982
Publication status	Published - 2022

Keywords

CETUXIMAB PLUS IRINOTECAN
PHASE-III TRIAL
1ST-LINE TREATMENT
RAS MUTATIONS
BRAF MUTATION
WILD-TYPE
MICROSATELLITE INSTABILITY
CANCER
FLUOROURACIL
LEUCOVORIN

Access to Document

10.21873/anticanres.15982

Cite this

Gerger, A., Eisterer, W., Fuxius, S., Bastian, S., Koeberle, D., Welslau, M., Sanoyan, DA., Maas, C., Uhlig, J., Fenchel, K., Greil, R., von der Heyde, E., Agocs, GR., Weide, R., Schwager, M., Reichenbach, F., Modest, DP., & Fritsch, R. (2022). Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC. ANTICANCER RESEARCH , 42(10), 4773-4785. https://doi.org/10.21873/anticanres.15982

Gerger, A ; Eisterer, W ; Fuxius, S et al. / Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC. In: ANTICANCER RESEARCH 2022 ; Vol. 42, No. 10. pp. 4773-4785.

@article{fee608706c3b402d9e3d07acb6e5f02b,

title = "Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC",

keywords = "CETUXIMAB PLUS IRINOTECAN, PHASE-III TRIAL, 1ST-LINE TREATMENT, RAS MUTATIONS, BRAF MUTATION, WILD-TYPE, MICROSATELLITE INSTABILITY, CANCER, FLUOROURACIL, LEUCOVORIN",

author = "A Gerger and W Eisterer and S Fuxius and S Bastian and D Koeberle and M Welslau and DA Sanoyan and C Maas and J Uhlig and K Fenchel and Richard Greil and {von der Heyde}, E and GR Agocs and R Weide and M Schwager and F Reichenbach and DP Modest and R Fritsch",

note = "[Greil, R.] Salzburg Cancer Research Institute – Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Paracelsus Medical University, Salzburg, Austria;",

year = "2022",

doi = "10.21873/anticanres.15982",

language = "English",

volume = "42",

pages = "4773--4785",

journal = "ANTICANCER RESEARCH ",

number = "10",

}

Gerger, A, Eisterer, W, Fuxius, S, Bastian, S, Koeberle, D, Welslau, M, Sanoyan, DA, Maas, C, Uhlig, J, Fenchel, K, Greil, R, von der Heyde, E, Agocs, GR, Weide, R, Schwager, M, Reichenbach, F, Modest, DP & Fritsch, R 2022, 'Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC', ANTICANCER RESEARCH , vol. 42, no. 10, pp. 4773-4785. https://doi.org/10.21873/anticanres.15982

Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC. / Gerger, A; Eisterer, W; Fuxius, S et al.
In: ANTICANCER RESEARCH , Vol. 42, No. 10, 2022, p. 4773-4785.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC

AU - Gerger, A

AU - Eisterer, W

AU - Fuxius, S

AU - Bastian, S

AU - Koeberle, D

AU - Welslau, M

AU - Sanoyan, DA

AU - Maas, C

AU - Uhlig, J

AU - Fenchel, K

AU - Greil, Richard

AU - von der Heyde, E

AU - Agocs, GR

AU - Weide, R

AU - Schwager, M

AU - Reichenbach, F

AU - Modest, DP

AU - Fritsch, R

N1 - [Greil, R.] Salzburg Cancer Research Institute – Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Paracelsus Medical University, Salzburg, Austria;

PY - 2022

Y1 - 2022

KW - CETUXIMAB PLUS IRINOTECAN

KW - PHASE-III TRIAL

KW - 1ST-LINE TREATMENT

KW - RAS MUTATIONS

KW - BRAF MUTATION

KW - WILD-TYPE

KW - MICROSATELLITE INSTABILITY

KW - CANCER

KW - FLUOROURACIL

KW - LEUCOVORIN

U2 - 10.21873/anticanres.15982

DO - 10.21873/anticanres.15982

M3 - Original Article

C2 - 36191968

VL - 42

SP - 4773

EP - 4785

JO - ANTICANCER RESEARCH

JF - ANTICANCER RESEARCH

IS - 10

ER -

Gerger A, Eisterer W, Fuxius S, Bastian S, Koeberle D, Welslau M et al. Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC. ANTICANCER RESEARCH . 2022;42(10):4773-4785. doi: 10.21873/anticanres.15982